Challenges of advanced hepatocellular carcinoma

被引:127
作者
Colagrande, Stefano [1 ]
Inghilesi, Andrea L. [2 ]
Aburas, Sami [2 ]
Taliani, Gian G. [1 ]
Nardi, Cosimo
Marra, Fabio [2 ]
机构
[1] Univ Florence, Dipartimento Sci Biomed Sperimentali & Clin, I-50134 Florence, Italy
[2] Univ Florence, Dipartimento Med Sperimentale & Clin, Ctr Ric Denothe, I-50134 Florence, Italy
关键词
Barcelona Clinic Liver Cancer; Portal vein thrombosis; Modified Response Evaluation Criteria in Solid Tumors; Advanced hepatocellular carcinoma management; Advanced hepatocellular carcinoma second line therapies; Sorafenib; CHAIN AMINO-ACIDS; RESPONSE EVALUATION CRITERIA; ALPHA-FETOPROTEIN RESPONSE; CANCER-RELATED FATIGUE; SOLID TUMORS RECIST; PORTAL-VEIN; PHASE-III; TRANSARTERIAL CHEMOEMBOLIZATION; DOUBLE-BLIND; 1ST-LINE THERAPY;
D O I
10.3748/wjg.v22.i34.7645
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause of death by cancer each year. The management of patients with HCC is complex, as both the tumour stage and any underlying liver disease must be considered conjointly. Although surveillance by imaging, clinical and biochemical parameters is routinely performed, a lot of patients suffering from cirrhosis have an advanced stage HCC at the first diagnosis. Advanced stage HCC includes heterogeneous groups of patients with different clinical condition and radiological features and sorafenib is the only approved treatment according to Barcelona Clinic Liver Cancer. Since the introduction of sorafenib in clinical practice, several phase. clinical trials have failed to demonstrate any superiority over sorafenib in the frontline setting. Loco-regional therapies have also been tested as first line treatment, but their role in advanced HCC is still matter of debate. No single agent or combination therapies have been shown to impact outcomes after sorafenib failure. Therefore this review will focus on the range of experimental therapeutics for patients with advanced HCC and highlights the successes and failures of these treatments as well as areas for future development. Specifics such as dose limiting toxicity and safety profile in patients with liver dysfunction related to the underlying chronic liver disease should be considered when developing therapies in HCC. Finally, robust validated and reproducible surrogate end-points as well as predictive biomarkers should be defined in future randomized trials.
引用
收藏
页码:7645 / 7659
页数:15
相关论文
共 123 条
[1]   Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature [J].
Abdel-Rahman, Omar ;
Fouad, Mona .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 91 (01) :1-8
[3]   Shaping the Future Management of Hepatocellular Carcinoma [J].
Abou-Alfa, Ghassan ;
Colombo, Massimo .
SEMINARS IN LIVER DISEASE, 2013, 33 :S20-S23
[4]   Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance) [J].
Abou-Alfa, Ghassan K. ;
Niedzwieski, Donna ;
Knox, Jennifer J. ;
Kaubisch, Andreas ;
Posey, James ;
Tan, Benjamin R. ;
Kavan, Petr ;
Goel, Rakesh ;
Lammers, Philip Edward ;
Bekaii-Saab, Tanios S. ;
Tam, Vincent Channing ;
Rajdev, Lakshmi ;
Kelley, Robin Kate ;
Siegel, Abby B. ;
Balletti, Jennifer ;
Harding, James J. ;
Howard, Lawrence Schwartz ;
Goldberg, Richard M. ;
Bertagnolli, Monica M. ;
Venook, Alan P. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5]   Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial [J].
Abou-Alfa, Ghassan K. ;
Johnson, Philip ;
Knox, Jennifer J. ;
Capanu, Marinela ;
Davidenko, Irina ;
Lacava, Juan ;
Leung, Thomas ;
Gansukh, Bolorsukh ;
Saltz, Leonard B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (19) :2154-2160
[6]  
Ahmed N., 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD003445.PUB2, 10.1002/14651858.CD003445.pub2]
[7]   Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma [J].
Arizumi, Tadaaki ;
Ueshima, Kazuomi ;
Takeda, Haruhiko ;
Osaki, Yukio ;
Takita, Masahiro ;
Inoue, Tatsuo ;
Kitai, Satoshi ;
Yada, Norihisa ;
Hagiwara, Satoru ;
Minami, Yasunori ;
Sakurai, Toshiharu ;
Nishida, Naoshi ;
Kudo, Masatoshi .
JOURNAL OF GASTROENTEROLOGY, 2014, 49 (12) :1578-1587
[8]  
Assenat E, 2013, J CLIN ONCOL, V31
[9]   Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward? [J].
Bargellini, Irene ;
Scionti, Alessandra ;
Mismas, Valeria ;
Masi, Gianluca ;
Vivaldi, Caterina ;
Bartolozzi, Carlo ;
Sacco, Rodolfo .
ONCOLOGY, 2014, 86 (04) :191-198
[10]   Hepatocellular carcinoma: clinical frontiers and perspectives [J].
Bruix, Jordi ;
Gores, Gregory J. ;
Mazzaferro, Vincenzo .
GUT, 2014, 63 (05) :844-855